LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
VIR
Vir Biotechnology, Inc.
There isn't enough reported data to score VIR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VIR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Under pressure | |
| Strong |
VIR's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VIR PE Valuation
VIR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
VIR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect VIR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
VIR Earnings Per Share
VIR and LLY do not have enough comparable growth data to identify a winner.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over VIR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over VIR on profitability, with a higher operating margin.
VIR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $238.9M | +19583% |
| Q4 2025 | $64.1M | +418% |
| Q3 2025 | $240K | -90% |
| Q2 2025 | $1.2M | -61% |
| Q1 2025 | $3M | -95% |
| Q4 2024 | $12.4M | -26% |
| Q3 2024 | $2.4M | -9.8% |
| Q2 2024 | $3.1M | -19% |
VIR's revenue is recovering but still below its 2022 peak: $239M last quarter, up 19583% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 31% | +9785 points |
| Q4 2025 | -75% | +872 points |
| Q3 2025 | -72268% | -62549 points |
| Q2 2025 | -9754% | -4596 points |
| Q1 2025 | -4602% | -4460 points |
| Q4 2024 | -947% | -119 points |
| Q3 2024 | -9719% | -2643 points |
| Q2 2024 | -5159% | +509 points |
VIR's operating margin was 31% last quarter, up 4633 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over VIR on cash generation, producing positive trailing cash flow while its opponent burns cash.
VIR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $123.3M | +$246.1M |
| Q1 2026 | -$132.8M | -$53M |
| Q4 2025 | -$26.2M | +$63.8M |
| Q3 2025 | -$167.9M | +$5.9M |
| Q2 2025 | -$122.8M | -$44.2M |
| Q1 2025 | -$79.7M | +$31.5M |
| Q4 2024 | -$90M | +$19.4M |
| Q3 2024 | -$173.8M | -$14.3M |
VIR has burned cash in most quarters: −$204M over the past year, against −$466M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VIR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VIR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +15% | +21.5M shares |
| 1 year | +22% | +30.4M shares |
| 3 years | +26% | +34.8M shares |
| 5 years | +26% | +35.1M shares |
| Available history | +56% | +60.5M shares |
VIR has 169M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q2 2022 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VIR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -1.0x | Net Cash |
| Q3 2022 | -0.6x | Net Cash |
| Q2 2022 | -1.1x | Net Cash |
| Q1 2022 | -0.5x | Net Cash |
| Q4 2021 | -0.8x | Net Cash |
VIR has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VIR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.2 | Neutral |
| Stochastic | 76.5 | Neutral |
VIR's weekly RSI is 63 (neutral) and its Stochastic is 76 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VIR PE vs Healthcare Sector
| Metric | VIR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VIR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
VIR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.2 | 8.1% above |
| 20 week MA | $10.4 | 17% above |
| 50 week MA | $9.12 | 33% above |
| 100 week MA | $7.75 | 56% above |
| 200 week MA | $10.7 | 13% above |
VIR has climbed back above all five of its weekly moving averages, and it's now 13% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
VIR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.4 | $29.5 | +139% |
| 2021 | $29.5 | $41.8 | +41% |
| 2022 | $41.8 | $25.7 | -38% |
| 2023 | $25.7 | $10.1 | -61% |
| 2024 | $10.1 | $7.47 | -26% |
| 2025 | $7.47 | $6.00 | -20% |
| 2026 YTD | $6.00 | $12.1 | +102% |
VIR has the edge over LLY on returns for 2026, with the stronger performance.